Monrovia, CA, August 09, 2008 --(PR.com
)-- Dr. Ashraf Hanna, Vice President of Alliance Management and Portfolio Planning at Genentech in San Francisco, CA will present at the Plenary Keynote session at GTCbio’s 4th Modern Drug Discovery and Development Summit on October 15-17, 2008 in La Jolla, CA.
Dr. Hanna will present on The Cost and Benefit of Portfolio Innovation. In his presentation, Dr. Hanna will review historical drug development costs and its impact on society. He will assess the current environment for drug development and answer such questions as “Is innovation in the pharmaceutical industry threatened?” Finally, Dr. Hanna will outline possible trends to consider that we can impact to maintain a focus on scientific progress and improved treatments for patients.
The 4th Modern Drug Discovery & Development Summit features over 150 speakers participating in 6 concurrent conferences, 6 mini sessions and 3 short symposia. Other plenary speakers include John Doll, Commissioner of Patents at the US Patent & Trademark Office, David Nicholson, SVP of Global Project Management at Schering Plough, Keith James, SVP & Site Head at Pfizer La Jolla, Johan Luthman, Global Head of Exploratory Medicine Neurology at MerckSerono and Sandy Macrae, VP of Business Development at GlaxoSmithKline. The 6 tracks will cover Biological Therapeutics, Translational Medicine, Drug Design & Lead Optimization, Emerging Targets &, Pharmacokinetics & Pharmacodynamics and Partnering, Licensing & Outsourcing. For more information, visit www.gtcbio.com.
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Their goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, firstname.lastname@example.org